Previous close | 0.3000 |
Open | 0.3000 |
Bid | 0.1500 |
Ask | 0.3500 |
Strike | 17.50 |
Expiry date | 2024-06-21 |
Day's range | 0.3000 - 0.3000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
BEDFORD, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on June 3, 2024, Anika granted: (i) non-statutory stock options (“Options”) covering 96,525 shares of common stock at a per share exercise price of $29.35, which equaled 110% of the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, and (ii) restricted stock units (
Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP (“Caligan”). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed
Anika Therapeutics ( NASDAQ:ANIK ) First Quarter 2024 Results Key Financial Results Revenue: US$40.5m (up 6.9% from 1Q...